LAGi-DEL 

LAGi-DEL is a LAG-3 inhibitor, with K_d values of 97.33 nM and 271 nM in surface plasmon resonance (SPR) assay and microscale thermophoresis (MST) assay, respectively. LAGi-DEL blocks the LAG-3/MHC-II interaction, with an EC₅₀ of 138 nM. LAGi-DEL restores T cell activation, enhances IFN-γ secretion and promotes immune-mediated cytotoxicity. LAGi-DEL can be used in the research of acute myeloid leukemia, lung cancer and melanoma^[1].

LAGi-DEL (10 μM; 24 h) restores T cell activation, elevates IFN-γ secretion, and promotes immune-mediated killing of THP-1 human acute myeloid leukemia cells in a PBMC co-culture model^[1].
LAGi-DEL (10 μM; 24 h) restores T cell activation, elevates IFN-γ secretion, and promotes immune-mediated killing of A549 human lung carcinoma cells in a PBMC co-culture model^[1].
LAGi-DEL exhibits favorable drug-like properties including high aqueous solubility, moderate permeability, acceptable metabolic and plasma stability, low cytotoxicity to normal cells, negligible hERG and CYP liabilities, and no mutagenic activity^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

530.59

C₂₈H₂₆N₄O₅S

CNC(C[C@H](C1=CC(OC)=CC(OC)=C1)NC(C2=C(NC(N3)=O)C3=CC(C4=C(SC=C5)C5=CC=C4)=C2)=O)=O

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Nada H, et al. Discovery and validation of LAGi-DEL: A nanomolar LAG-3 inhibitor that reverses immune suppression in tumor-immune co-culture models. Eur J Med Chem. 2026;301:118204.  [Content Brief]